scholarly journals Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data

2014 ◽  
Vol 17 (3) ◽  
pp. 245-253 ◽  
Author(s):  
P. Levin ◽  
W. Wei ◽  
R. Miao ◽  
F. Ye ◽  
L. Xie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Electronic Medical Records ◽  
Real World ◽  
Medical Records ◽  
Basal Insulin ◽  
Insulin Analogues

scholarly journals Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study

2020 ◽  
Vol 13 ◽  
pp. 117955142093593
Author(s):  
Chaicharn Deerochanawong ◽  
Rattana Leelawattana ◽  
Natapong Kosachunhanun ◽  
Puntip Tantiwong
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Real World ◽  
Basal Insulin ◽  
Insulin Dose ◽  
Dose Titration ◽  
Glycemic Targets

This multicenter, longitudinal, descriptive, observational study of T2DM adults in Thailand aimed to assess real-world outcomes of basal insulin (BI) dose titration on glycemic control. Three-hundred and twenty-four patients were recruited and followed up over 24 weeks. Basal insulin titration was physician-driven in 58.2% of patients and patient-driven in the rest. During the 24-week study period, the total daily BI dose moved from 20.9 to 25.6 in the physician-driven group, while in the patient-driven group, it increased from 25.3 to 29.7. Thirty-five patients (11.2%) achieved their individualized HbA1c targets, with 18 patients (5.8%) achieving HbA1c ⩽ 7% without documented hypoglycemia. In summary, this study highlights that BI titration is suboptimal in the real world, and patients are unable to achieve their glycemic targets.

Sign in / Sign up

Export Citation Format

Share Document